

Teresa Lambe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1298550/publications.pdf>

Version: 2024-02-01

123
papers

26,794
citations

20759

60
h-index

17055

122
g-index

159
all docs

159
docs citations

159
times ranked

31212
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
2	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	6.3	2,080
3	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	6.3	1,196
4	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. <i>New England Journal of Medicine</i> , 2021, 384, 1885-1898.	13.9	1,077
5	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
6	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. <i>Cell</i> , 2021, 184, 2348-2361.e6.	13.5	936
7	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	15.2	900
8	ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. <i>Nature</i> , 2020, 586, 578-582.	13.7	840
9	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. <i>Cell</i> , 2022, 185, 467-484.e15.	13.5	788
10	A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. <i>Nature</i> , 2005, 435, 452-458.	13.7	777
11	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , 2021, 184, 4220-4236.e13.	13.5	630
12	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	6.3	540
13	Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. <i>Cell</i> , 2022, 185, 2422-2433.e13.	13.5	532
14	Antibody evasion by the P.1 strain of SARS-CoV-2. <i>Cell</i> , 2021, 184, 2939-2954.e9.	13.5	519
15	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCoV-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. <i>Lancet, The</i> , 2021, 398, 2258-2276.	6.3	519
16	DNA repair is limiting for haematopoietic stem cells during ageing. <i>Nature</i> , 2007, 447, 686-690.	13.7	475
17	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	15.2	473
18	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. <i>Cell</i> , 2021, 184, 2201-2211.e7.	13.5	442

#	ARTICLE	IF	CITATIONS
19	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. <i>Lancet, The</i> , 2021, 398, 856-869.	6.3	430
20	Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1. <i>Clinical Infectious Diseases</i> , 2011, 52, 1-7.	2.9	424
21	Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. <i>Lancet, The</i> , 2022, 399, 234-236.	6.3	318
22	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. <i>Lancet, The</i> , 2022, 399, 521-529.	6.3	314
23	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. <i>New England Journal of Medicine</i> , 2016, 374, 1635-1646.	13.9	295
24	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265
25	Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. <i>Science</i> , 2021, 371, 79-82.	6.0	247
26	Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production. <i>Nature Immunology</i> , 2009, 10, 1283-1291.	7.0	236
27	Preliminary Assessment of the Efficacy of a T-Cell-Based Influenza Vaccine, MVA-NP+M1, in Humans. <i>Clinical Infectious Diseases</i> , 2012, 55, 19-25.	2.9	224
28	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021, 398, 981-990.	6.3	214
29	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV, the</i> , 2021, 8, e474-e485.	2.1	190
30	Polyethylimine is a potent mucosal adjuvant for viral glycoprotein antigens. <i>Nature Biotechnology</i> , 2012, 30, 883-888.	9.4	189
31	Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 816-826.	4.6	182
32	Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	180
33	DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice. <i>Journal of Experimental Medicine</i> , 2011, 208, 2305-2320.	4.2	175
34	Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens. <i>Molecular Therapy</i> , 2014, 22, 668-674.	3.7	165
35	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. <i>Lancet, The</i> , 2022, 399, 36-49.	6.3	161
36	Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else?. <i>Experimental Dermatology</i> , 2008, 17, 139-140.	1.4	148

#	ARTICLE	IF	CITATIONS
37	Viral vectors as vaccine platforms: from immunogenicity to impact. <i>Current Opinion in Immunology</i> , 2016, 41, 47-54.	2.4	137
38	ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. <i>Vaccine</i> , 2017, 35, 3780-3788.	1.7	133
39	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. <i>Lancet HIV</i> , 2021, 8, e568-e580.	2.1	124
40	Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. <i>Npj Vaccines</i> , 2020, 5, 69.	2.9	121
41	Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. <i>ACS Central Science</i> , 2021, 7, 594-602.	5.3	118
42	Cellular and developmental aspects of androgenetic alopecia. <i>Experimental Dermatology</i> , 1998, 7, 235-248.	1.4	117
43	Immune privilege or privileged immunity?. <i>Mucosal Immunology</i> , 2008, 1, 372-381.	2.7	111
44	Themis is a member of a new metazoan gene family and is required for the completion of thymocyte positive selection. <i>Nature Immunology</i> , 2009, 10, 831-839.	7.0	108
45	A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years. <i>PLoS ONE</i> , 2012, 7, e48322.	1.1	107
46	DOCK8 is essential for T _H 1 cell survival and the maintenance of CD8 ⁺ T _H 1 cell memory. <i>European Journal of Immunology</i> , 2011, 41, 3423-3435.	1.6	105
47	Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. <i>Cell</i> , 2022, 185, 2116-2131.e18.	13.5	105
48	Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. <i>Nature Communications</i> , 2021, 12, 2893.	5.8	104
49	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. <i>Nature Communications</i> , 2021, 12, 2055.	5.8	102
50	Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults. <i>EBioMedicine</i> , 2018, 29, 146-154.	2.7	100
51	A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques. <i>Science Advances</i> , 2020, 6, eaba8399.	4.7	89
52	High Glucose-altered Gene Expression in Mesangial Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 9707-9712.	1.6	88
53	MAIT cell activation augments adenovirus vector vaccine immunogenicity. <i>Science</i> , 2021, 371, 521-526.	6.0	88
54	The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world. <i>Immunology</i> , 2020, 160, 223-232.	2.0	86

#	ARTICLE	IF	CITATIONS
55	Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. <i>Npj Vaccines</i> , 2017, 2, 28.	2.9	81
56	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T _H 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
57	Identification of a Steap3 endosomal targeting motif essential for normal iron metabolism. <i>Blood</i> , 2009, 113, 1805-1808.	0.6	75
58	CD4 T Cell-Dependent Autoimmunity against a Melanocyte Neoantigen Induces Spontaneous Vitiligo and Depends upon Fas-Fas Ligand Interactions. <i>Journal of Immunology</i> , 2006, 177, 3055-3062.	0.4	74
59	CD4+ T Follicular Helper Cells in Human Tonsils and Blood Are Clonally Convergent but Divergent from Non-Tfh CD4+ Cells. <i>Cell Reports</i> , 2020, 30, 137-152.e5.	2.9	74
60	Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels. <i>Scientific Reports</i> , 2019, 9, 16292.	1.6	72
61	DOCK8 is critical for the survival and function of NKT cells. <i>Blood</i> , 2013, 122, 2052-2061.	0.6	68
62	Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1. <i>Scientific Reports</i> , 2013, 3, 1443.	1.6	67
63	What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins. <i>EBioMedicine</i> , 2016, 8, 277-290.	2.7	67
64	Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 3020-3032.	1.4	67
65	A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice. <i>Med</i> , 2021, 2, 243-262.e8.	2.2	62
66	Limited Peripheral T Cell Anergy Predisposes to Retinal Autoimmunity. <i>Journal of Immunology</i> , 2007, 178, 4276-4283.	0.4	54
67	MyD88-dependent autoimmune disease in Lyn-deficient mice. <i>European Journal of Immunology</i> , 2007, 37, 2734-2743.	1.6	54
68	ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7. <i>Nature Communications</i> , 2021, 12, 5868.	5.8	52
69	Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge. <i>Frontiers in Immunology</i> , 2019, 10, 2005.	2.2	48
70	ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets. <i>Npj Vaccines</i> , 2021, 6, 67.	2.9	47
71	CITED1 homozygous null mice display aberrant pubertal mammary ductal morphogenesis. <i>Oncogene</i> , 2006, 25, 1532-1542.	2.6	46
72	A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007462.	1.3	46

#	ARTICLE	IF	CITATIONS
73	Improved adjuvanting of seasonal influenza vaccines: Preclinical studies of <sc>MVA&NP+M</sc> 1 coadministration with inactivated influenza vaccine. <i>European Journal of Immunology</i> , 2013, 43, 1940-1952.	1.6	43
74	Vaccine platforms for the prevention of Lassa fever. <i>Immunology Letters</i> , 2019, 215, 1-11.	1.1	43
75	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.. <i>Journal of Infection</i> , 2022, 84, 795-813.	1.7	43
76	Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya. <i>Nature Communications</i> , 2021, 12, 3966.	5.8	40
77	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. <i>PLoS Pathogens</i> , 2021, 17, e1009804.	2.1	39
78	Manufacturing a chimpanzee adenovirus&vectored SARS&CoV&2 vaccine to meet global needs. <i>Biotechnology and Bioengineering</i> , 2022, 119, 48-58.	1.7	38
79	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. <i>Nature Communications</i> , 2021, 12, 5861.	5.8	38
80	Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7). <i>SSRN Electronic Journal</i> , 0, , .	0.4	36
81	Clinical Advances in Viral-Vectored Influenza Vaccines. <i>Vaccines</i> , 2018, 6, 29.	2.1	35
82	A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160295.	1.8	33
83	Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice. <i>Vaccine</i> , 2019, 37, 5567-5577.	1.7	33
84	Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 356-359.	4.6	32
85	A naturally protective epitope of limited variability as&an influenza vaccine target. <i>Nature Communications</i> , 2018, 9, 3859.	5.8	32
86	Hyper IgE in New Zealand black mice due to a dominant-negative CD23 mutation. <i>Immunogenetics</i> , 2004, 56, 564-571.	1.2	31
87	Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	31
88	ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge. <i>Npj Vaccines</i> , 2021, 6, 32.	2.9	30
89	HLA-E: exploiting pathogen-host interactions for vaccine development. <i>Clinical and Experimental Immunology</i> , 2019, 196, 167-177.	1.1	28
90	Viral vector vaccines. <i>Current Opinion in Immunology</i> , 2022, 77, 102210.	2.4	28

#	ARTICLE	IF	CITATIONS
91	Measuring Cellular Immunity to Influenza: Methods of Detection, Applications and Challenges. <i>Vaccines</i> , 2015, 3, 293-319.	2.1	26
92	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. <i>JCI Insight</i> , 2022, 7, .	2.3	26
93	Spontaneous B cell hyperactivity in autoimmune-prone MRL mice. <i>International Immunology</i> , 2006, 18, 1127-1137.	1.8	24
94	The Essential Role of DOCK8 in Humoral Immunity. <i>Disease Markers</i> , 2010, 29, 141-150.	0.6	24
95	Novel Viral Vectored Vaccines for the Prevention of Influenza. <i>Molecular Medicine</i> , 2012, 18, 1153-1160.	1.9	24
96	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. <i>JCI Insight</i> , 2022, 7, .	2.3	24
97	B-cell Tolerance. <i>Transplantation</i> , 2006, 81, 308-315.	0.5	23
98	T-Cell Responses in Children to Internal Influenza Antigens, 1 Year After Immunization With Pandemic H1N1 Influenza Vaccine, and Response to Revaccination With Seasonal Trivalentâ€“inactivated Influenza Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, e86-e91.	1.1	23
99	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. <i>EBioMedicine</i> , 2022, 77, 103902.	2.7	23
100	Expression and Cellular Immunogenicity of a Transgenic Antigen Driven by Endogenous Poxviral Early Promoters at Their Authentic Loci in MVA. <i>PLoS ONE</i> , 2012, 7, e40167.	1.1	22
101	Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. <i>Science Advances</i> , 2021, 7, eabg7996.	4.7	20
102	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, 1251.	5.8	20
103	The Threshold of Protection from Liver-Stage Malaria Relies on a Fine Balance between the Number of Infected Hepatocytes and Effector CD8+ T Cells Present in the Liver. <i>Journal of Immunology</i> , 2017, 198, 2006-2016.	0.4	17
104	Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge. <i>Journal of Immunology</i> , 2017, 199, 1333-1341.	0.4	16
105	Modified Vaccinia Ankaraâ€“Vectored Vaccine Expressing Nucleoprotein and Matrix Protein 1 (M1) Activates Mucosal M1-Specific T-Cell Immunity and Tissue-Resident Memory T Cells in Human Nasopharynx-Associated Lymphoid Tissue. <i>Journal of Infectious Diseases</i> , 2020, 222, 807-819.	1.9	16
106	ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models. <i>Communications Biology</i> , 2021, 4, 915.	2.0	15
107	Detection of Vaccine-Induced Antibodies to Ebola Virus in Oral Fluid. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw031.	0.4	13
108	Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines. <i>Vaccine</i> , 2016, 34, 1688-1695.	1.7	13

#	ARTICLE	IF	CITATIONS
109	Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. <i>Vaccine</i> , 2016, 34, 49-55.	1.7	13
110	A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector. <i>Vaccines</i> , 2020, 8, 241.	2.1	12
111	The essential role of DOCK8 in humoral immunity. <i>Disease Markers</i> , 2010, 29, 141-50.	0.6	12
112	Differential expression of connexin 43 in mouse mammary cells. <i>Cell Biology International</i> , 2006, 30, 472-479.	1.4	10
113	Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine. <i>SSRN Electronic Journal</i> , 0, , .	0.4	10
114	The Integration of Human and Veterinary Studies for Better Understanding and Management of Crimean-Congo Haemorrhagic Fever. <i>Frontiers in Immunology</i> , 2021, 12, 629636.	2.2	8
115	Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility. <i>Journal of Virological Methods</i> , 2022, 302, 114475.	1.0	8
116	An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females. <i>EBioMedicine</i> , 2022, 81, 104128.	2.7	8
117	Recombinant protein vaccines against SARS-CoV-2. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1337-1338.	4.6	6
118	CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination. <i>JCI Insight</i> , 2022, 7, .	2.3	6
119	Respiratory and Intramuscular Immunization With ChAdOx2-NPM1-NA Induces Distinct Immune Responses in H1N1pdm09 Pre-Exposed Pigs. <i>Frontiers in Immunology</i> , 2021, 12, 763912.	2.2	5
120	Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
121	Why do breakthrough COVID-19 infections occur in the vaccinated?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2022, 115, 67-68.	0.2	2
122	Commmentary 7. <i>Experimental Dermatology</i> , 2008, 17, 157-158.	1.4	0
123	Response to Letter to the Editor by Ish et al. entitled "COVID-19 vaccine equity"the need of the hour"™. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2022, , .	0.2	0